8137.Full.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

8137.Full.Pdf Analysis of Direct and Cross-Presentation of Antigens in TPPII Knockout Mice 1 Elke Firat, Jisen Huai, Loredana Saveanu, Simone Gaedicke, Peter Aichele, Klaus Eichmann, Peter van Endert and This information is current as Gabriele Niedermann of September 29, 2021. J Immunol 2007; 179:8137-8145; ; doi: 10.4049/jimmunol.179.12.8137 http://www.jimmunol.org/content/179/12/8137 Downloaded from References This article cites 37 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/179/12/8137.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Analysis of Direct and Cross-Presentation of Antigens in TPPII Knockout Mice1 Elke Firat,2* Jisen Huai,2* Loredana Saveanu,† Simone Gaedicke,* Peter Aichele,‡ Klaus Eichmann,§ Peter van Endert,† and Gabriele Niedermann3* Tripeptidyl peptidase II (TPPII) is an oligopeptidase forming giant complexes in the cytosol that have high exo-, but also, endoproteolytic activity. Immunohistochemically, the complexes appear as distinct foci in the cytosol. In part controversial bio- chemical and functional studies have suggested that TPPII contributes, on the one hand, positively to Ag processing by generating epitope carboxyl termini or by trimming epitope precursors, and, on the other, negatively by destroying potentially antigenic peptides. To clarify which of these roles is predominant, we generated and analyzed TPPII-deficient mice. Cell surface levels of MHC class I peptide complexes tended to be increased on most cell types of these mice. Although presentation of three individual ؊ ؊ epitopes derived from lymphocytic choriomeningitis virus was not elevated on TPPII / cells, that of the immunodominant OVA Downloaded from epitope SIINFEKL was significantly enhanced. Consistent with this, degradation of a synthetic peptide corresponding to the OVA epitope and of another corresponding to a precursor thereof, both being proteasomally generated OVA fragments, was delayed in TPPII-deficient cytosolic extracts. In addition, dendritic cell cross-presentation of phagocytosed OVA and of OVA internalized as an immune complex was increased to about the same level as direct presentation of the Ag. The data suggest a moderate, predominantly destructive role of TPPII in class I Ag processing, in line with our finding that TPPII is not induced by IFN-␥, which up-regulates numerous, predominantly constructive components of the Ag processing and presentation machinery. The http://www.jimmunol.org/ Journal of Immunology, 2007, 179: 8137–8145. ells present samples of their protein content to CTLs via (Ct) (4) aa. Their cleavage preferences thus perfectly match the the proteolytic generation of peptides in the cytosol, preferences of human TAP and of the vast majority of MHC class C which after transport to the endoplasmic reticulum (ER)4 I alleles for the Ct peptide position. Thus, in many cases, protea- are loaded onto MHC class I molecules, which then migrate to the somes produce the epitope as well as epitope precursors, as has cell surface. The displayed peptides are 8–10 aa long. The TAP repeatedly been shown in in vitro digestion experiments (1, 3, 5). transporter in the ER membrane prefers peptides of 8–15 aa, im- Of the downstream peptidases, the ER-aminopeptidase associ- by guest on September 29, 2021 plying that both peptides corresponding to epitopes and epitope ated with Ag processing or endoplasmic reticulum-associated ami- precursors are translocated into the ER, where final trimming of nopeptidase (ERAP)1, has been investigated most intensively. epitope precursors can occur (1–3). ERAP1 appears to be the only ER-associated trimming peptidase Cytosolic endo- and aminopeptidases and ER-resident amin- in mice. Although the knockout (KO) of ERAP1 significantly re- opeptidases, but not carboxypeptidases, operate in the classical duces cell surface MHC class I expression, only a subset of epitope class I Ag processing pathway (4). Proteasomes are in many cases precursor peptides is trimmed down to final epitope size by involved in the initial processing steps. They preferentially gener- ERAP1, whereas other epitope or epitope precursor peptides are ate peptides of 3–20 aa with a hydrophobic or charged C-terminal destroyed or unaffected (6–9). ERAP2, which is exclusively ex- pressed in humans, forms in part complexes with ERAP1, and both aminopeptidases are required to efficiently trim certain epitope pre- cursor sequences (10). *Clinic for Radiotherapy, University Hospital of Freiburg, Freiburg, Germany; †In- Of the many cytosolic peptidases, leucine aminopeptidase stitut National de la Sante´et de la Recherche Me´dicale, Universite´Paris Descartes, Faculte´deMe´decine Rene´Descartes, Paris, France; ‡Institute for Medical Microbi- (LAP), thimet oligopeptidase (TOP), puromycin sensitive amino- ology and Hygiene, Department of Immunology, University of Freiburg, Freiburg, peptidase (PSA), bleomycin hydrolase, and tripeptidyl peptidase II Germany; and §Max-Planck Institute of Immunobiology, Freiburg, Germany (TPPII) have been implicated in class I Ag processing (4, 11). The Received for publication August 7, 2007. Accepted for publication October 15, 2007. endo-oligopeptidase TOP prefers peptides of 9–16 aa and prefer- 1 This work was supported by the Deutsche Forschungsgemeinschaft (NI 368/4–2), entially destroys potential epitopes and epitope precursors (12). In the Clotten Foundation, and a grant from the Forschungskommission of the University of Freiburg Medical Faculty (NIE346/04). vitro digestion and protease inhibitor experiments suggested that the aminopeptidases LAP, bleomycin hydrolase, and PSA signif- 2 E.F. and J.H. contributed equally to this work. icantly contribute to cytosolic epitope precursor trimming, but 3 Address correspondence and reprint requests to Dr. Gabriele Niedermann, Clinic for Radiotherapy, University Hospital of D-79106 Freiburg, Freiburg, Germany. E-mail studies performed in KO mice could not confirm this (13, 14). address: [email protected] With a molecular mass of ϳ6 MDa, TPPII forms the largest 4 Abbreviations used in this paper: ER, endoplasmic reticulum; Ct, C-terminal; protease complex of eukaryotic cells. These complexes are com- ERAP, endoplasmic reticulum-associated aminopeptidase; LAP, leucine aminopepti- posed of 40 identical subunits with a molecular mass of 140 kDa, dase; TOP, thimet oligopeptidase; PSA, puromycin sensitive aminopeptidase; TPPII, tripeptidyl peptidase II; KO, knockout; AAF-CMK alanine-alanine-phenylalanine- arranged in two twisted strands (15). Degradation of short and long chloromethyl ketone; DCs, dendritic cells; BM, bone marrow; LCMV, lymphocytic (up to 40 aa) oligopeptides but not proteins has been demonstrated choriomeningitis virus; VV, vaccinia virus; ID, immunodominant; WT, wild type. with purified TPPII complexes in vitro. The complexes have a Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00 highly active aminotripeptidase, and some endopeptidase activity. www.jimmunol.org 8138 Ag PROCESSING IN TPPII KNOCKOUT MICE TPPII’s endopeptidase preferentially cleaves after lysine and argi- incubation with LPS (10 ␮g/ml; Sigma-Adrich) or IFN-␥ (200 U/ml; eBio- nine in long substrates (16–18). Peptides with Ct lysine residues science). Cell lysates were separated by SDS-PAGE. The blots were are not efficiently produced by proteasomes, but are preferred by probed with rabbit peptide-specific anti-TPPII Abs and goat polyclonal anti-actin Abs and developed by ECL (Amersham Biosciences). some HLA class I alleles such as HLA-A3 and HLA-A11, whose ligands may therefore be produced by alternative proteases (19). Cloning of EGFP-TPPII Purified TPPII precisely excises an HLA-A3/A11-restricted HIV- The murine TPPII c-DNA was amplified from genomic DNA by long- Nef epitope with a Ct lysine from its flanking sequences and TPPII range PCR. After subcloning into the Bluescript vector (Stratagene), the knockdown significantly reduces recognition of the epitope by insert was sequenced. EGFP was fused to the N terminus of TPPII and the CTLs (17). TPPII is thus the first and so far only nonproteasomal EGFP-TPPII fusion protein was cloned into pcDNA3 (Invitrogen) by stan- protease to be shown to generate the C terminus of a CTL epitope. dard cloning procedures. COS-7 cells were transfected using DEAE dex- tran and analyzed after 36 h by fluorescence microscopy. TPPII seems also to be required for generation of the influenza Separation of cell extracts on gel filtration columns NP147–155 epitope as suggested by siRNA and protease inhibitor experiments using the broadly specific serine protease inhibitor High molecular
Recommended publications
  • The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.28.317750; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome is Evolutionarily Conserved Authors Peter Kubiniok†1, Ana Marcu†2,3, Leon Bichmann†2,4, Leon Kuchenbecker4, Heiko Schuster1,5, David Hamelin1, Jérome Despault1, Kevin Kovalchik1, Laura Wessling1, Oliver Kohlbacher4,7,8,9,10 Stefan Stevanovic2,3,6, Hans-Georg Rammensee2,3,6, Marian C. Neidert11, Isabelle Sirois1, Etienne Caron1,12* Affiliations *Corresponding and Leading author: Etienne Caron ([email protected]) †Equal contribution to this work 1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 3Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 4Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen, Baden- Württemberg, 72074, Germany. 5Immatics Biotechnologies GmbH, Tübingen, 72076, Baden-Württemberg, Germany. 6DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen, Baden- Württemberg, 72076, Germany. 7Institute for Bioinformatics and Medical Informatics,
    [Show full text]
  • Supplemental Materials Supplemental Table 1
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Supplemental Materials Supplemental Table 1. The differentially expressed proteins from rat pancreas identified by proteomics (SAP vs. SO) No. Protein name Gene name ratio P value 1 Metallothionein Mt1m 3.35 6.34E-07 2 Neutrophil antibiotic peptide NP-2 Defa 3.3 8.39E-07 3 Ilf2 protein Ilf2 3.18 1.75E-06 4 Numb isoform o/o rCG 3.12 2.73E-06 5 Lysozyme Lyz2 3.01 5.63E-06 6 Glucagon Gcg 2.89 1.17E-05 7 Serine protease HTRA1 Htra1 2.75 2.97E-05 8 Alpha 2 macroglobulin cardiac isoform (Fragment) 2.75 2.97E-05 9 Myosin IF (Predicted) Myo1f 2.65 5.53E-05 10 Neuroendocrine secretory protein 55 Gnas 2.61 7.60E-05 11 Matrix metallopeptidase 8 Mmp8 2.57 9.47E-05 12 Protein Tnks1bp1 Tnks1bp1 2.53 1.22E-04 13 Alpha-parvin Parva 2.47 1.78E-04 14 C4b-binding protein alpha chain C4bpa 2.42 2.53E-04 15 Protein KTI12 homolog Kti12 2.41 2.74E-04 16 Protein Rab11fip5 Rab11fip5 2.41 2.84E-04 17 Protein Mcpt1l3 Mcpt1l3 2.33 4.43E-04 18 Phospholipase B-like 1 Plbd1 2.33 4.76E-04 Aldehyde dehydrogenase (NAD), cytosolic 19 2.32 4.93E-04 (Fragments) 20 Protein Dpy19l2 Dpy19l2 2.3 5.68E-04 21 Regenerating islet-derived 3 alpha, isoform CRA_a Reg3a 2.27 6.74E-04 22 60S acidic ribosomal protein P1 Rplp1 2.26 7.22E-04 23 Serum albumin Alb 2.25 7.98E-04 24 Ribonuclease 4 Rnase4 2.24 8.25E-04 25 Cct-5 protein (Fragment) Cct5 2.24 8.52E-04 26 Protein S100-A9 S100a9 2.22 9.71E-04 27 Creatine kinase M-type Ckm 2.21 1.00E-03 28 Protein Larp4b Larp4b 2.18 1.25E-03
    [Show full text]
  • Leishmania (L.) Amazonensis Peptidase Activities Inside the Living Cells and in Their Lysates
    Molecular & Biochemical Parasitology 184 (2012) 82–89 Contents lists available at SciVerse ScienceDirect Molecular & Biochemical Parasitology Leishmania (L.) amazonensis peptidase activities inside the living cells and in their lysates a a b c a Elide E. Caroselli , Diego M. Assis , Clara L. Barbiéri , Wagner A.S. Júdice , Maria A. Juliano , d a,∗ Marcos L. Gazarini , Luiz Juliano a Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, SP, Brazil b Department of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, SP, Brazil c Centro Interdisciplinar de Investigac¸ ão Bioquímica, Universidade de Mogi das Cruzes, Av. Dr. Cândido Xavier de Almeida Souza 200, 08780-911 Mogi das Cruzes, Brazil d Department of Biosciences, Universidade Federal de São Paulo, Santos, Brazil a r t i c l e i n f o a b s t r a c t Article history: In this study we investigated the peptidase activity in Leishmania (L.) amazonensis live amastigote by con- Received 24 November 2011 focal microscopy using peptidyl-MCA as substrates, the hydrolysis of which releases the MCA fluorophore Received in revised form 13 March 2012 inside the cells. Cell pre-treatment with peptidase inhibitors indicated the presence of cysteine and ser- Accepted 27 April 2012 ine peptidases. It was noteworthy that Leishmania amastigotes incorporate only substrates (Z-FR-MCA, Available online 6 May 2012 Z-RR-MCA) or inhibitors (E64, TLCK) containing positively charged groups. The peptidase activities in the supernatants of amastigotes and promastigotes lysates were also evaluated with the same peptidyl-MCA Keywords: substrates and inhibitors in the pH range 4.5–9.0.
    [Show full text]
  • Supplementary Table 9. Functional Annotation Clustering Results for the Union (GS3) of the Top Genes from the SNP-Level and Gene-Based Analyses (See ST4)
    Supplementary Table 9. Functional Annotation Clustering Results for the union (GS3) of the top genes from the SNP-level and Gene-based analyses (see ST4) Column Header Key Annotation Cluster Name of cluster, sorted by descending Enrichment score Enrichment Score EASE enrichment score for functional annotation cluster Category Pathway Database Term Pathway name/Identifier Count Number of genes in the submitted list in the specified term % Percentage of identified genes in the submitted list associated with the specified term PValue Significance level associated with the EASE enrichment score for the term Genes List of genes present in the term List Total Number of genes from the submitted list present in the category Pop Hits Number of genes involved in the specified term (category-specific) Pop Total Number of genes in the human genome background (category-specific) Fold Enrichment Ratio of the proportion of count to list total and population hits to population total Bonferroni Bonferroni adjustment of p-value Benjamini Benjamini adjustment of p-value FDR False Discovery Rate of p-value (percent form) Annotation Cluster 1 Enrichment Score: 3.8978262119731335 Category Term Count % PValue Genes List Total Pop Hits Pop Total Fold Enrichment Bonferroni Benjamini FDR GOTERM_CC_DIRECT GO:0005886~plasma membrane 383 24.33290978 5.74E-05 SLC9A9, XRCC5, HRAS, CHMP3, ATP1B2, EFNA1, OSMR, SLC9A3, EFNA3, UTRN, SYT6, ZNRF2, APP, AT1425 4121 18224 1.18857065 0.038655922 0.038655922 0.086284383 UP_KEYWORDS Membrane 626 39.77128335 1.53E-04 SLC9A9, HRAS,
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Studies of Structure and Function of Tripeptidyl-Peptidase II
    Till familj och vänner List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I. Eriksson, S.; Gutiérrez, O.A.; Bjerling, P.; Tomkinson, B. (2009) De- velopment, evaluation and application of tripeptidyl-peptidase II se- quence signatures. Archives of Biochemistry and Biophysics, 484(1):39-45 II. Lindås, A-C.; Eriksson, S.; Josza, E.; Tomkinson, B. (2008) Investiga- tion of a role for Glu-331 and Glu-305 in substrate binding of tripepti- dyl-peptidase II. Biochimica et Biophysica Acta, 1784(12):1899-1907 III. Eklund, S.; Lindås, A-C.; Hamnevik, E.; Widersten, M.; Tomkinson, B. Inter-species variation in the pH dependence of tripeptidyl- peptidase II. Manuscript IV. Eklund, S.; Kalbacher, H.; Tomkinson, B. Characterization of the endopeptidase activity of tripeptidyl-peptidase II. Manuscript Paper I and II were published under maiden name (Eriksson). Reprints were made with permission from the respective publishers. Contents Introduction ..................................................................................................... 9 Enzymes ..................................................................................................... 9 Enzymes and pH dependence .............................................................. 11 Peptidases ................................................................................................. 12 Serine peptidases ................................................................................. 14 Intracellular protein
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • Table 4. V. Cholerae Flexgene ORF Collection
    Table 4. V. cholerae FLEXGene ORF collection Reference Clone protein PlasmID clone GenBank Locus tag Symbol accession identifier FLEX clone name accession Product name VC0001 NP_062585 VcCD00019918 FLH200476.01F DQ772770 hypothetical protein VC0002 mioC NP_062586 VcCD00019938 FLH200506.01F DQ772771 mioC protein VC0003 thdF NP_062587 VcCD00019958 FLH200531.01F DQ772772 thiophene and furan oxidation protein ThdF VC0004 yidC NP_062588 VcCD00019970 FLH200545.01F DQ772773 inner membrane protein, 60 kDa VC0005 NP_062589 VcCD00061243 FLH236482.01F DQ899316 conserved hypothetical protein VC0006 rnpA NP_062590 VcCD00025697 FLH214799.01F DQ772774 ribonuclease P protein component VC0007 rpmH NP_062591 VcCD00061229 FLH236450.01F DQ899317 ribosomal protein L34 VC0008 NP_062592 VcCD00019917 FLH200475.01F DQ772775 amino acid ABC transporter, ATP-binding protein VC0009 NP_062593 VcCD00019966 FLH200540.01F DQ772776 amino acid ABC transproter, permease protein VC0010 NP_062594 VcCD00019152 FLH199275.01F DQ772777 amino acid ABC transporter, periplasmic amino acid-binding portion VC0011 NP_062595 VcCD00019151 FLH199274.01F DQ772778 hypothetical protein VC0012 dnaA NP_062596 VcCD00017363 FLH174286.01F DQ772779 chromosomal DNA replication initiator DnaA VC0013 dnaN NP_062597 VcCD00017316 FLH174063.01F DQ772780 DNA polymerase III, beta chain VC0014 recF NP_062598 VcCD00019182 FLH199319.01F DQ772781 recF protein VC0015 gyrB NP_062599 VcCD00025458 FLH174642.01F DQ772782 DNA gyrase, subunit B VC0016 NP_229675 VcCD00019198 FLH199346.01F DQ772783 hypothetical protein
    [Show full text]
  • Proteases in MHC Class I Presentation and Cross-Presentation Kenneth L
    Proteases in MHC Class I Presentation and Cross-Presentation Kenneth L. Rock, Diego J. Farfán-Arribas and Lianjun Shen This information is current as J Immunol 2010; 184:9-15; ; of October 1, 2021. doi: 10.4049/jimmunol.0903399 http://www.jimmunol.org/content/184/1/9 References This article cites 79 articles, 36 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/184/1/9.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Proteases in MHC Class I Presentation and Cross-Presentation Kenneth L. Rock, Diego J. Farfa´n-Arribas, and Lianjun Shen Cells that have mutated their genes or are virally is tolerant to them. However, if cells are synthesizing mutant infected are a potential threat to a host. Consequently, proteins or ones from viruses, then peptides from these gene the immune system has evolved mechanisms for CD8 T products will also be displayed, and this allows effector CD8 lymphocytes to identify such cells and eliminate them.
    [Show full text]
  • Supplementary Table 2: Infection-Sensitive Genes
    Supplementary Table 2: Infection-Sensitive Genes Supplementary Table 2: Upregulated with Adenoviral Infection (pages 1 - 7)- genes that were significant by ANOVA as well as significantly increased in control compared to both 'infected control' (Ad-LacZ) and 'calcineurin infected' (Ad-aCaN). Downregulated with Adenoviral Infection (pages 7 - 13) as above except for direction of change. Columns: Probe Set- Affymetrix probe set identifier for RG-U34A microarray, Symbol and Title- annotated information for above probe set (annotation downloaded June, 2004), ANOVA- p-value for 1-way Analysis of Variance, Uninfected, Ad-LacZ and Ad- aCaN- mean ± SEM expression for uninfected control, adenovirus mediated LacZ treated control, and adenovirus mediated calcineurin treated cultures respectively. Upregulated with Adenoviral Infection Probe Set Symbol Title ANOVA Uninfected Ad-LacZ Ad-aCaN Z48444cds_at Adam10 a disintegrin and metalloprotease domain 10 0.00001 837 ± 31 1107 ± 24 1028 ± 29 L26986_at Adcy8 adenylyl cyclase 8 0.00028 146 ± 12 252 ± 21 272 ± 21 U94340_at Adprt ADP-ribosyltransferase 1 0.00695 2096 ± 100 2783 ± 177 2586 ± 118 U01914_at Akap8 A kinase anchor protein 8 0.00080 993 ± 44 1194 ± 65 1316 ± 44 AB008538_at Alcam activated leukocyte cell adhesion molecule 0.01012 2775 ± 136 3580 ± 216 3429 ± 155 M34176_s_at Ap2b1 adaptor-related protein complex 2, beta 1 subunit 0.01389 2408 ± 199 2947 ± 143 3071 ± 116 D44495_s_at Apex1 apurinic/apyrimidinic endonuclease 1 0.00089 4959 ± 185 5816 ± 202 6057 ± 158 U16245_at Aqp5 aquaporin 5 0.02710
    [Show full text]
  • Genome-Wide Profiling of Druggable Active Tumor Defense Mechanisms to Enhance Cancer Immunotherapy
    bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy Rigel J. Kishton1,2,*,#, Shashank J. Patel1,2,†,*, Suman K. Vodnala1,2, Amy E. Decker3, Yogin Patel1,2, Madhusudhanan Sukumar1,2, Tori N. Yamamoto1,2,4, Zhiya Yu1,2, Michelle Ji1,2, Amanda N. Henning1,2, Devikala Gurusamy1,2, Douglas C. Palmer1,2, Winifred Lo1, Anna Pasetto1, Parisa Malekzadeh1, Drew C. Deniger1, Kris C. Wood3, Neville E. Sanjana5,6, Nicholas P. Restifo1,2, #, § 1Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2Center for Cell-Based Therapy, National Cancer Institute, Bethesda, MD 20892, USA 3Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, USA 4Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA 5New York Genome Center, New York, NY 10013 USA 6Department of Biology, New York University, New York, NY 10003, USA *These authors contributed equally to this work. †Present address: NextCure Inc., Beltsville, MD 20705, USA §Present address: Lyell Immunopharma, South San Francisco, CA 94080, USA #Corresponding authors. NPR: [email protected]. RJK: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]
  • Pa28αβ: the Enigmatic Magic Ring of the Proteasome?
    Biomolecules 2014, 4, 566-584; doi:10.3390/biom4020566 OPEN ACCESS biomolecules ISSN 2218-273X www.mdpi.com/journal/biomolecules/ Review PA28: The Enigmatic Magic Ring of the Proteasome? Paolo Cascio Department of Veterinary Sciences, University of Turin, Grugliasco 10095, Italy; E-Mail: [email protected]; Tel.: +39-011-670-9113; Fax: +39-011-670-9138 Received: 4 April 2014; in revised form: 15 May 2014 / Accepted: 8 June 2014 / Published: 19 June 2014 Abstract: PA28 is a -interferon-induced 11S complex that associates with the ends of the 20S proteasome and stimulates in vitro breakdown of small peptide substrates, but not proteins or ubiquitin-conjugated proteins. In cells, PA28 also exists in larger complexes along with the 19S particle, which allows ATP-dependent degradation of proteins; although in vivo a large fraction of PA28 is present as PA28-20S particles whose exact biological functions are largely unknown. Although several lines of evidence strongly indicate that PA28 plays a role in MHC class I antigen presentation, the exact molecular mechanisms of this activity are still poorly understood. Herein, we review current knowledge about the biochemical and biological properties of PA28 and discuss recent findings concerning its role in modifying the spectrum of proteasome’s peptide products, which are important to better understand the molecular mechanisms and biological consequences of PA28 activity. Keywords: PA28; proteasomes; immunoproteasomes; protein degradation; MHC class I antigen presentation; epitopes; antigenic peptides 1. MHC Class I Antigen Presentation The continual presentation of intracellular proteins fragments on major histocompatibility complex (MHC) class I molecules is a process that allows cytotoxic CD8+ T lymphocytes (CTLs) to identify and selectively eliminate cells that synthesize foreign (e.g., viral) or abnormal (e.g., oncogene products) proteins [1,2].
    [Show full text]